<kbd id='QtFBtMNbohF5vo5'></kbd><address id='QtFBtMNbohF5vo5'><style id='QtFBtMNbohF5vo5'></style></address><button id='QtFBtMNbohF5vo5'></button>

              <kbd id='QtFBtMNbohF5vo5'></kbd><address id='QtFBtMNbohF5vo5'><style id='QtFBtMNbohF5vo5'></style></address><button id='QtFBtMNbohF5vo5'></button>

                      <kbd id='QtFBtMNbohF5vo5'></kbd><address id='QtFBtMNbohF5vo5'><style id='QtFBtMNbohF5vo5'></style></address><button id='QtFBtMNbohF5vo5'></button>

                              <kbd id='QtFBtMNbohF5vo5'></kbd><address id='QtFBtMNbohF5vo5'><style id='QtFBtMNbohF5vo5'></style></address><button id='QtFBtMNbohF5vo5'></button>

                                      <kbd id='QtFBtMNbohF5vo5'></kbd><address id='QtFBtMNbohF5vo5'><style id='QtFBtMNbohF5vo5'></style></address><button id='QtFBtMNbohF5vo5'></button>

                                              <kbd id='QtFBtMNbohF5vo5'></kbd><address id='QtFBtMNbohF5vo5'><style id='QtFBtMNbohF5vo5'></style></address><button id='QtFBtMNbohF5vo5'></button>

                                                      <kbd id='QtFBtMNbohF5vo5'></kbd><address id='QtFBtMNbohF5vo5'><style id='QtFBtMNbohF5vo5'></style></address><button id='QtFBtMNbohF5vo5'></button>

                                                              <kbd id='QtFBtMNbohF5vo5'></kbd><address id='QtFBtMNbohF5vo5'><style id='QtFBtMNbohF5vo5'></style></address><button id='QtFBtMNbohF5vo5'></button>

                                                                  凯时娱乐官网下载_DNF手游下载专区(metroplace.net)最新ag旗舰厅手机版app游戏大全官网下载地址,请登录我们第一DNF手游视频视角-最专业的DNF手游技能娱乐门户首页

                                                                  手机阅读

                                                                  m.metroplace.net

                                                                  Biocartis Group NV: Study Demonstrates Ability of Idylla(TM

                                                                  更新日期: 2018-07-09 11:11 来源 :凯时娱乐官网下载

                                                                    May 28, 2018 01:01ET|Source:Biocartis Group NV

                                                                    <strong>multilang-releasestrong>

                                                                    PRESS RELEASE: 28 May 2018, 07:00 CEST

                                                                    Study Demonstrates Ability of Idylla(TM) EGFR Mutation Test to Produce a Result in 80% of Failed Next Generation Sequencing Lung Cancer Tests

                                                                    Mechelen, Belgium, 28 May 2018- Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announcesthe publication of a study[1]in the Journal of Clinical Pathology demonstrating that the Idylla(TM) EGFR Mutation Test (CE-IVD) was able to rescue 80% of the EGFR samples whose assessment was unsuccessful with Next Generation Sequencing (NGS). The study concluded that the Idylla(TM) EGFR Mutation Test is a viable alternative to NGS for rapid treatment decisions[2]in patients with acute deterioration, in particular when testing is performed on a less than optimal tumor tissue sample, which frequently yields insufficient amounts of DNA for proper NGS analysis.

                                                                    Thestudy, conducted by amongst others Prof. Giancarlo Troncone, Professor of Anatomic Pathology of the Department of Public Health, University of Naples Federico II (Naples, Italy) and Prof. Massimo Barberis, Director of Histopathology and Molecular Diagnostics Unit of the Division of Pathology and Laboratory Medicine, Istituto Europeo di Oncologia (Milan, Italy), included 68 archival DNA samples previously processed by NGS[3]. A total of 43 had a valid NGS result and 25 (37%) had an invalid NGS result. These samples were retested by directly pipetting[4]the DNA[5]into the Idylla(TM) EGFR Mutation Test cartridge. There was a 100% concordance with NGS for the valid results, where Idylla(TM) confirmed the EGFR mutational status. For a large portion (20/25 or 80%) of the cases whose NGS assessment was invalid, Idylla(TM) was able to process the sample and adequately produced a result. In 4/25 (16%) of these cases, Idylla(TM) detected actionable EGFR mutations, which means a larger patient population that could potentially benefit from targeted treatments.

                                                                    Lung cancer testing today is often complex because of the limited amount of lung cancer tissue available, which frequently leads to failure of test results. The Idylla(TM) EGFR Mutation Test is performed on Biocartis' Idylla(TM) system and allows the detection of 51 EGFR mutations, which are included in international guidelines[6]for all patients with advanced NSCLC[7]of a non-squamous subtype, directly from only one slice of FFPE[8]tumor tissue. The test delivers results in approx. 2.5 hours with less than 2 minutes hands-on time.

                                                                    Giancarlo Troncone, MD, PhD, Professor of Anatomic Pathology, University of Naples Federico II (Naples, Italy), commented:"Timely communication between oncologists and molecular pathologists is crucial, in particular for acute deteriorating patient clinical management. Our data showed that, when clinical decisions should be taken quickly to save time since days have been spent on waiting for an invalid NGS result, Idylla(TM) can provide a solution."

                                                                    Lung cancer is the cancer with the highest incidence worldwide[9]. The launch of Biocartis' fully automated Idylla(TM) liquid biopsy ctEGFR Mutation Assay (RUO[10]) is planned for H2 2018.

                                                                    [1]De Luca et al, University of Naples Federico II, "The Idylla(TM) Assay and Next Generation Sequencing: an integrated EGFR mutational testing algorithm", Journal of Clinical Pathology, to consult online on?ijkey=V8eBoaMDpKZ7t9N&keytype=ref, 24 May 2018.

                                                                    [2]To be taken by a multidisciplinary team.

                                                                    [3]Ion Torrent NGS Assay by Thermo Fisher Scientific Inc, USA.

                                                                    [4]Cases with a valid NGS result were tested by pipetting 3 microliter of DNA (corresponding to 1/10th of the original DNA preparation from the sample) in the Idylla(TM) EGFR Mutation Test cartridge. Whenever possible, in NGS invalid cases the pipetted DNA volume was increased up to 10microliterof extracted DNA. It was previously shown that archival extracted DNA can directly be pipetted inside an Idylla(TM) EGFR Mutation Test cartridge: Source: De Luca et al., "EGFR mutation on lung cancer cytological specimens by the novel fully automated PCR-based Idylla(TM) EGFR Mutation Assay", J Clin Pathol. 2017; 70:295-300.

                                                                    [5]Biocartis has not validated this sample type for clinical use with its Idylla(TM) EGFR Mutation Test (CE IVD).

                                                                    [6]NCCN Clinical Practice Guidelines in Oncology - NSCLC - Version 3.2018, and Novello S. et al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2016.

                                                                    [7]Non-small cell lung cancer

                                                                    [8]Formalin fixed, parrafin embedded.

                                                                    [9]

                                                                    [10]RUO = Research Use Only.

                                                                    --- END ---

                                                                    More information:

                                                                    Renate Degrave

                                                                    Manager Corporate Communications & Investor Relations

                                                                    e-mailrdegrave@biocartis.com

                                                                    tel  +32 15 631 729

                                                                    mobile  +32 471 53 60 64

                                                                    About Biocartis

                                                                  相关文章
                                                                  斗罗来袭
                                                                  斗罗来袭2018年07月08日
                                                                  手机游戏网是中国最具影响力的手游新媒体之一。驻足于手机游戏行业,致力于为玩家提供最出色的手机游戏,并为行业职员提供资深的行业资讯。手游游戏网专注于手游...[详细]
                                                                  腾讯2015新品宣布会 DNF移动版来袭
                                                                  新浪DNF专区是DNF官方相助专区,专区提供DNF剑豪,DNF职业联赛,DNF女鬼剑等职业比赛视频,DNF补丁下载,DNF皮肤下载,DNF全职业攻略等优质内容....[详细]
                                                                  张召忠盛赞《战舰天下》今天发号下载
                                                                  张召忠盛赞《战舰天下》今天发号下载先容了闻名军事理论家、军事评述家张召忠做客空中网。进一步相识《战舰天下》。同时不删档测试激活码发放和客户端下载今天同...[详细]
                                                                  <strong>3K游戏《战争时候》周年庆典 将领军备</strong>
                                                                  3K游戏旗下当代战争游戏——3K游戏《战争时候》一岁啦!从2016年7月14日在3K游戏平台独代首发,到本日为止,列位批示官随同3K游戏《战争时候》走过了难以忘怀的...[详细]
                                                                  <strong>腾讯UP前瞻:7款端游仅1款新品 DNF手</strong>
                                                                  腾讯UP前瞻:7款端游仅1款新品 DNF手游版或上线,...[详细]
                                                                  用户为王杀出红海,《传奇盛世2》上线
                                                                  传奇IP进驻中国游戏界至今已有17年,依然是当下最热点的游戏范例之一。然而游戏市场里充斥着大量传奇类页游、手游和私服端游,大多是以消用度户的情怀与氪金至上...[详细]
                                                                  你可能喜欢
                                                                  免责声明:DNF手游下载专区所有DNF手游视频文字、DNF手游技能图片、视频、音频等资料均来自互联网,不代表本站赞同其观点,本站亦不为其版权负责。DNF手游发布相关作品的原创性、文中陈述文字以及内容数据庞杂本站无法一一核实,如果您发现本网站上有侵犯您的合法权益的内容,请联系我们,本网站将立即予以删除!
                                                                  ©Copyright 2014-2018 DNF手游下载专区-凯时娱乐官网下载_凯时娱乐下载地址_凯时娱乐游戏大厅下载  http://www.metroplace.net 版权所有